Clinical Trial Update: Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase II study of PLM60 for relapsed cutaneous T-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• PLM60

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Relapsed Cutaneous T Cell Lymphom | Phase 2 | Status: TERMINATED